Financial reports
10-K
2023 FY
Annual report
12 Mar 24
10-Q
2023 Q3
Quarterly report
6 Nov 23
10-Q
2023 Q2
Quarterly report
11 Aug 23
10-Q
2023 Q1
Quarterly report
9 May 23
ARS
2022 FY
Annual report to shareholders
4 Apr 23
10-K
2022 FY
Annual report
9 Mar 23
10-Q
2022 Q3
Quarterly report
8 Nov 22
10-Q
2022 Q2
Quarterly report
9 Aug 22
10-Q
2022 Q1
Quarterly report
11 May 22
10-K
2021 FY
Annual report
17 Mar 22
Current reports
8-K
Black Diamond Therapeutics Announces Changes to Board of Directors
11 Apr 24
8-K
Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
12 Mar 24
8-K
Departure of Directors or Certain Officers
18 Jan 24
8-K
Black Diamond Therapeutics Announces Corporate Update and Expected 2024 Milestones
4 Jan 24
8-K
Black Diamond Therapeutics Announces Topline Results from Phase 1 Dose Escalation Trial of BDTX-1535 in Patients with Recurrent GBM
13 Dec 23
8-K
Black Diamond Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
6 Nov 23
8-K
Black Diamond Therapeutics Announces CEO Transition
18 Sep 23
8-K
Black Diamond Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
11 Aug 23
8-K
Entry into a Material Definitive Agreement
30 Jun 23
8-K
Regulation FD Disclosure
27 Jun 23
Registration and prospectus
S-8
Registration of securities for employees
12 Mar 24
424B5
Prospectus supplement for primary offering
30 Jun 23
424B5
Prospectus supplement for primary offering
29 Jun 23
S-8
Registration of securities for employees
9 Mar 23
S-3
Shelf registration
14 Nov 22
S-8
Registration of securities for employees
17 Mar 22
S-8
Registration of securities for employees
25 Mar 21
S-3ASR
Automatic shelf registration
1 Feb 21
S-8
Registration of securities for employees
30 Jan 20
424B4
Prospectus supplement with pricing info
30 Jan 20
Proxies
PRE 14A
Preliminary proxy
12 Apr 24
DEFA14A
Additional proxy soliciting materials
4 Apr 23
DEF 14A
Definitive proxy
4 Apr 23
DEFA14A
Additional proxy soliciting materials
28 Apr 22
DEF 14A
Definitive proxy
28 Apr 22
DEFA14A
Additional proxy soliciting materials
29 Apr 21
DEF 14A
Definitive proxy
27 Apr 21
Other
EFFECT
Notice of effectiveness
23 Nov 22
CORRESP
Correspondence with SEC
18 Nov 22
UPLOAD
Letter from SEC
17 Nov 22
EFFECT
Notice of effectiveness
30 Jan 20
CERT
Certification of approval for exchange listing
29 Jan 20
CORRESP
Correspondence with SEC
27 Jan 20
CORRESP
Correspondence with SEC
27 Jan 20
CORRESP
Correspondence with SEC
21 Jan 20
CORRESP
Correspondence with SEC
13 Jan 20
UPLOAD
Letter from SEC
10 Jan 20
Ownership